comparison of glp-1 agonists for weight loss Vs Tirzepatide: Powerful Guide To Better Comparative efficacy and safety of
Description
642653, Nov
These may include injection site reactions, mild to moderate nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite
Positive chronotropic and inotropic effects in heart failure have been demonstrated with infusions of GLP-1 in animal studies and small short-term studies of patients with acute heart failure post-myocardial infarction and in patients with chronic systolic and diastolic dysfunction.12 Tirzepatide has demonstrated additional benefits of slowing renal decline when used in conjunction with insulin and reduced all-cause mortality compared with other GLP-1RAs.13 In patients with type 2 diabetes mellitus (T2DM), reductions in composite renal outcomes and renal failure have been outlined in meta-analyses.14 Of great interest for gastroenterologists and hepatologists is the potential for using GLP-1 agonists in metabolic dysfunction-associated steatotic liver disease (MASLD)
54.FDA Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Some patients also experience bloating, diarrhea, or general stomach discomfort
When they come back to Earth, their muscles are a little bit weaker, and many show decreased bone density
